-
Eli Lilly's basal insulin BIF has a hypoglycemic effect comparable to Novo Nordisk insulin
Time of Update: 2021-04-27
CompilenewbornAccording to a phase 2 clinical trial (NCT03736785), a new once-a-week basal insulin injection has similar efficacy and safety compared with once-a-day basal insulin, and has a lower incidence of hypoglycemia.
-
7 new domestically produced Class 1 anti-ED drugs are coming, and Yangtze River sprints for the first time!
Time of Update: 2021-04-27
The fourth domestic anti-ED oral PDE-5 inhibitor strikes, Haisco will win the first imitation A few days ago, Sichuan Haisco entered the administrative examination and approval stage with imitation 3 types of avanafil tablets, which is expected to be approved in the near future.
-
The State Food and Drug Administration Revises the Instructions for Mouse Nerve Growth Factor for Injection
Time of Update: 2021-04-27
On March 23, the State Food and Drug Administration issued an announcement on the revision of the instructions for mouse nerve growth factor for injection, and decided to revise the instructions for mouse nerve growth factor for injection [adverse reactions], [precautions] and medications for special populations.
-
Fosun Pharma's stock price fell on suspension of vaccination of two batches of new crown vaccine! The company responded urgently...
Time of Update: 2021-04-27
On March 16, 2020, Fosun Pharma and the company reached a new crown vaccine research and development cooperation, and was authorized to operate in mainland China and Clinical trials, listing applications and commercialization in Hong Kong, Macau and Taiwan.
-
Macau suspends vaccination of mRNA COVID-19 vaccine today due to defective packaging
Time of Update: 2021-04-27
The Macao Coordinating Center for Coordination of New Coronavirus Infections said on the 24th that the Macao Health Bureau has received a written notice from Fosun Industrial (Hong Kong) Company, as it has recently noticed a number of mRNAs produced by Baintech Biopharmaceutical with batch number 210102.
-
A wholly-owned subsidiary of Tus Pharmaceuticals obtained the "Drug Production License"
Time of Update: 2021-04-27
The solid comprehensive preparation workshop and comprehensive extraction workshop production line involved in some of the fund-raising projects implemented by the Chinese Medicine Company have passed the on-site inspection of drug GMP compliance by the Hunan Provincial Drug Administration, and completed the modification record of the "Drug Production License".
-
6681 pharmaceutical companies were notified that multiple provinces have successively issued notices
Time of Update: 2021-04-27
According to the "Guiding Opinions of the National Medical Security Administration on Establishing a Medical Price and Recruitment Credit Evaluation System", the center organized platform-related pharmaceutical companies to submit the "Pharmaceutical Enterprise Price and Marketing Behavior Credit Commitment".
-
The final results of phase 3 clinical analysis of olaparib for ovarian cancer are released
Time of Update: 2021-04-27
Recently, "The Lancet-Oncology" published a double-blind, randomized, placebo-controlled phase 3 clinical trial of olaparib as maintenance treatment for patients with BRCA1/2 mutant platinum-sensitive recurrent ovarian cancer (SOLO2/ENGOT-Ov21) final analysis result.
-
The new requirements of the Health Commission affect a large number of secondary hospitals!
Time of Update: 2021-04-27
The "Task" clarified that, in order to improve the mental health service capabilities of medical institutions, 100% psychiatric hospitals in the pilot area have set up mental outpatient clinics, and 40% of general hospitals above the second level open mental (psychological) outpatient clinics.
-
AstraZeneca announces the latest phase 3 clinical results of the new crown vaccine
Time of Update: 2021-04-27
The Data Safety Monitoring Committee found no increased risk of thrombosis in 21,583 subjects who received at least one dose of the vaccine, and no CVST event was found in this clinical trial.
-
New drug Zegalogue for the treatment of severe hypoglycemia received FDA approval
Time of Update: 2021-04-27
Recently, the company announced that the US Food and Drug Administration (FDA) has approved Zegalogue (dasiglucagon) injection for the treatment of severe hypoglycemia in children and adults with diabetes aged 6 years and over.
-
Tibet Weixinkang Pharmaceutical Subsidiary Obtained Drug Registration Certificate for Mixed Glycoelectrolyte Injection
Time of Update: 2021-04-27
On March 26, Tibet Weixinkang Pharmaceutical issued an announcement that its wholly-owned subsidiary Baiyi Pharmaceutical received the "Drug Registration Certificate" for mixed glycoelectrolyte injection approved and issued by the State Drug Administration.
-
AstraZeneca announces phase 3 clinical trial of its new crown vaccine confirms safety and effectiveness
Time of Update: 2021-04-27
On March 25, AstraZeneca announced that the main analysis of the Phase 3 clinical trial of the new crown vaccine AZD1222 has obtained high-level positive results. The results confirmed that its effec
-
Janssen's new RSV fusion protein inhibitor plans to be included in breakthrough treatment varieties
Time of Update: 2021-04-27
Public information shows that JNJ-53718678 is a new type of human RSV fusion protein inhibitor with the potential to treat respiratory syncytial virus infection.
Studies have found that the fusion glycoprotein (F) is essential for RSV to enter cells, which makes it an ideal target for researchers to develop RSV fusion protein inhibitors.
-
Yuan Dong, Ted...The siege surged by 300% injections! Osaikon is here too
Time of Update: 2021-04-27
0 Chinese Drug Evaluation DatabaseIn recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.
-
New news about essential medicines or increase in the proportion of essential medicines used
Time of Update: 2021-04-27
Medical Network News on March 23 Up-regulation ratio Recently, a circulating document shows that Jiangxi Province has recently adjusted the requirements for the proportion of essential medicines in public medical institutions.
-
More than 7,700 hospitals in my country have established an appointment diagnosis and treatment system
Time of Update: 2021-04-27
Medical Network News on March 24, National Health Commission’s Planning Development and Informatization Department Director Mao Qun’an said at a press conference of the National Health Commission on
-
Quotations from 265 pharmaceutical companies with 57 large varieties
Time of Update: 2021-04-24
265 pharmaceutical companies, competition is comingAccording to the "Notice on Carrying out Online Bargaining for the Sixth Batch of Guangxi Pharmaceutical Group Procurement (Second Batch) Varieties" issued by the Guangxi Pharmaceutical Group Procurement Service Platform, the Joint Procurement Office has determined the varieties and participating companies of this batch, which is scheduled for 2021 Online price negotiation will be conducted on April 7 (Wednesday).
-
"Going to sea" failed!
Time of Update: 2021-04-24
On the evening of April 9th, Kanghong Pharmaceutical issued an announcement stating that the global multi-center clinical trial of Conbercept ophthalmic injection was stopped, which means that its core product, Conbercept, which was highly anticipated by the market, failed to “go out to sea”.
-
CSPC JMT601 obtains clinical trial approval in the U.S.
Time of Update: 2021-04-24
. According to the announcement, JMT601 (CPO107) is the world’s first bispecific SIRPα fusion protein with a synergistic targeted binding effect that has entered the clinical stage.
The clinical data of these studies will lead the further development and approval of JMT601 (CPO107) for the treatment of non-Hodgkin's lymphoma and other hematological malignancies.
